Our technologies are born from peer-reviewed science and validated in rigorous clinical trials at Toronto University Hospital and partner institutions worldwide.
Selected key publications from the Advance Med Pro research programme.
We present QuantaFlux Spectral Mapping (QSM), a non-invasive 12-wavelength quantum dot system achieving 0.8μm-resolution mitochondrial metabolic mapping through intact skin. In a blinded validation cohort of 847 subjects across sepsis, metabolic syndrome, and oncological staging, QSM demonstrated 97.1% concordance with invasive mitochondrial biopsy findings while requiring zero patient preparation or tissue penetration.
Using BLRI's external BRET photonic excitation, we prospectively monitored 1,240 post-treatment cancer survivors. BLRI identified recurrence at 96.3% sensitivity and 94.1% specificity, consistently 14–21 days before PET-CT detectability. Importantly, all BLRI examinations required no contrast agent administration and produced no measurable adverse events.
In this RCT, 620 emergency department patients were randomised to standard venepuncture biochemistry versus ChromaDerm CDA. CDA produced a 47-biomarker panel with mean absolute error of 4.2% versus laboratory reference standards, in 0.4 seconds versus a median 67-minute lab turnaround time. Triage-to-treatment time was reduced by 38 minutes (p<0.001).
NeuroPulse Optical Mapping (NPOM) was evaluated in 186 ICU patients against simultaneous fMRI reference. NPOM achieved 1mm² spatial resolution and 200ms temporal resolution through intact skull bone, correctly classifying stroke penumbra boundaries in 94.6% of cases and detecting epileptiform activity with 91.3% concordance to simultaneous EEG.
282 patients with recalcitrant diabetic foot ulcers were randomised 1:1 to PWT or standard care. The PWT arm achieved complete wound closure 67% faster (median 18 vs. 55 days), with real-time PWT tissue diagnostic monitoring showing progressive improvement in tissue oxygenation and inflammatory burden with each session. Zero serious adverse events were recorded in the PWT group.
Advance Med Pro currently has 12 active and recruiting trials across Canada, the UK, and the Netherlands.
Evaluating QSM as an early-warning sepsis biomarker versus standard lactate and procalcitonin monitoring. Target n=1,800.
Longitudinal BLRI monitoring vs. standard imaging follow-up in 800 breast cancer survivors. Primary endpoint: lead-time to recurrence detection.
Assessing ChromaDerm accuracy and patient/family acceptability against standard blood draws in children aged 2–16 presenting to emergency. Target n=400.
Evaluating continuous NPOM monitoring during cardiac bypass surgery for real-time detection of cerebral hypoperfusion events. n=240.
Completed Phase II trial demonstrating 58% improvement in Stage III pressure injury healing with PWT versus placebo device. Results published 2023.
60-day wearable monitoring versus standard outpatient follow-up for 30-day readmission reduction in HFrEF patients. Target n=500.
Advance Med Pro's research is deeply embedded within the University of Toronto academic health network and international research consortia.
Dept. of Medical Biophysics — founding academic partner and IP co-holder
Primary clinical validation site across 14 departments
Oncology co-development and BLRI clinical trials
Paediatric ChromaDerm validation and CHROVET trial host
HEARTSENSE remote monitoring trial and cardiac ICU deployment
Federal research funding and National Research Council photonics labs
European NeuroPulse validation partnership — NHS pilot sites
QuantaFlux sepsis monitoring — Netherlands ICU consortium
Toronto innovation hub — commercialisation and scale-up partner
What we're building next — because the five breakthrough platforms are just the beginning.
Extending QuantaFlux quantum dot technology to non-contact retinal scanning, enabling early diabetic retinopathy and glaucoma detection through the pupil with no dilation drops, no contact lenses, and no mydriasis discomfort.
A wrist-worn device using spatially offset Raman spectroscopy (SORS) to assess bone mineral density and collagen crosslinking non-invasively — a potential DEXA replacement requiring no ionising radiation.
Building on BLRI photonics to specifically track PD-L1 expression changes and T-cell activation signatures during immunotherapy — enabling weekly non-invasive immune response profiling without repeat biopsies.
Pioneering the use of transabdominal near-infrared spectroscopy to detect shifts in gut microbiome metabolic activity — enabling non-invasive detection of dysbiosis, IBD flares, and C. difficile infections.
We actively welcome clinical research partnerships, academic collaborations, and industry co-development proposals.